WO2020111283A1 - 신규한 4-카보닐아미노-4-페닐피리미딘 화합물 또는 이의 약제학적으로 허용가능한 염 - Google Patents
신규한 4-카보닐아미노-4-페닐피리미딘 화합물 또는 이의 약제학적으로 허용가능한 염 Download PDFInfo
- Publication number
- WO2020111283A1 WO2020111283A1 PCT/KR2018/014574 KR2018014574W WO2020111283A1 WO 2020111283 A1 WO2020111283 A1 WO 2020111283A1 KR 2018014574 W KR2018014574 W KR 2018014574W WO 2020111283 A1 WO2020111283 A1 WO 2020111283A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- aminopyrimidin
- phenyl
- compound
- aryl
- alkyl
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
Definitions
- the present invention relates to a novel 4-carbonylamino-4-phenylpyrimidine compound or a pharmaceutically acceptable salt thereof.
- the novel compound of the present invention has the effect of preventing or treating obesity, diabetes or fatty liver.
- Obesity is more than energy metabolism due to imbalance of energy consumption and energy consumption, and consequently, fat cells are defined as an excess of triglyceride.
- Obesity is a chronic disease that is a worldwide problem and has no effective treatment and is a serious disease that continues to increase.
- Obesity unlike other diseases, has characteristics that accompany related diseases such as metabolic diseases, hypertension, diabetes, hyperlipidemia, arteriosclerosis, ischemic heart disease, fatty liver, and cholelithiasis, as well as weight gain, as well as weight gain.
- Diabetes is one of the leading causes of adult death worldwide, and the number of diabetics is rapidly increasing with the increase in the obese population, which is characterized by hyperglycemia due to excessive glucose production and peripheral insulin resistance.
- Fatty liver is caused by the accumulation of excess fat, especially triglyceride, in the liver tissue, and is generally diagnosed as fatty liver when more than 5% of the weight of the liver is accumulated.
- Fatty liver is classified as alcoholic and non-alcoholic fatty liver, and non-alcoholic fatty liver is mainly associated with obesity, diabetes, and hyperlipidemia.
- non-alcoholic fatty liver 42% higher arterial stiffness level than the non-alcoholic fatty liver, which shows a higher risk of arterial stiffness as the degree of fatty liver is severe, and the presence or absence of fatty liver may be considered as a risk factor for cardiovascular disease. It is known.
- Glutamate Dehydrogenase is widely distributed in bacterial, yeast, plant and animal tissues and is the only amino acid dehydrogenase that requires pyridine nucleotide as a coenzyme.
- Bacterial and yeast enzymes require NADP+
- plant enzymes NAD+ animal liver and kidney enzymes require NADP+ or NAD+, and the enzyme does not act on D-glutamic acid or other L-amino acids.
- GDH activators increase the ratio of NAD+/NADH , as in fasting or dietary conditions in the liver, and as a result, increase the activity of AMP-activated protein kinase (AMPK) and sirtuins, resulting in fatty acid biosynthesis and fasting in liver Suppress your life process.
- AMPK AMP-activated protein kinase
- sirtuins sirtuins
- Glutamate dehydrogenase activator BCH stimulating reductive amination prevents high fat/high fructose diet-induced steatohepatitis and hyperglycemia in C57BL/6J mice.Sci Rep. 2016 Nov 22;5:37468).
- AMPK AMPK and “sirtuins” activity is known to improve obesity by regulating energy consumption and appetite (AMPK and the neuroendocrine regulation of appetite and energy expenditure. Mol Cell Endocrinol. 2013 Feb 25;366(2):215-23 ).
- GDH secretes insulin by increasing the ATP and citric acid in the oxidative deamino reaction, thereby depolarizing and increasing the influx of calcium into the cells by the voltage-dependent calcium channel.
- Stimulating Triggering pathway
- increased citric acid is converted to acyl-CoAs to move the insulin prepared in the intracellular granular form to the cell membrane to continuously secrete insulin (Metabolic signaling). in fuel-induced insulin secretion.Cell Metab 2013; 18:162-185).
- the inventors of the present invention completed the present invention by confirming the possibility that the novel 4-carbonylamino-4-phenylpyrimidine compound or a pharmaceutically acceptable salt thereof shows GDH activity and can be used as a therapeutic agent for obesity, diabetes and fatty liver. Was done.
- Another object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of obesity, diabetes or fatty liver, comprising a novel 4-carbonylamino-4-phenylpyrimidine compound or a pharmaceutically acceptable salt thereof.
- Another object of the present invention is to provide a method for treating obesity, diabetes or fatty liver by administering a novel 4-carbonylamino-4-phenylpyrimidine compound or a pharmaceutically acceptable salt thereof to an obese, diabetic or fatty liver patient. Is to do.
- the present invention provides a novel compound of formula I: or a pharmaceutically acceptable salt thereof.
- R 1 is alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl or heteroaryl,
- R 2 is NR 3 R 4 ,
- R 3 and R 4 are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, heteroaryl, alkylcarbonyl, carboxyl or alkoxycarbonyl,
- the cycloalkyl, heterocyclic, aryl or heteroaryl is one selected from the group consisting of alkyl, alkenyl, alkynyl, hydroxy, halogen, amino, nitro, cyano, carbonyl, carboxyl, alkoxy, aryl and aryloxy. Can be substituted with the above substituents,
- alkyl, alkenyl or alkynyl may be substituted with one or more substituents selected from the group consisting of hydroxy, halogen, amino, nitro, cyano, carbonyl, carboxyl, alkoxy, cycloalkyl, heterocyclic, aryl and heteroaryl.
- substituents selected from the group consisting of hydroxy, halogen, amino, nitro, cyano, carbonyl, carboxyl, alkoxy, cycloalkyl, heterocyclic, aryl and heteroaryl.
- alkyl is C 1-30 alkyl
- Alkoxy is C 1-30 alkoxy
- Alkenyl is C 2-30 alkenyl
- Alkynyl is C 2-30 alkynyl
- Cycloalkyl is C 3-30 cycloalkyl
- Aryl is C 5-30 aryl
- Heterocyclic is a heterocyclic having 3 to 30 ring atoms in which one or more ring carbons are each replaced by a heteroatom selected from B, N, O or S,
- Heteroaryl is a heteroaryl having 3 to 30 ring atoms in which one or more ring carbons are each replaced with a heteroatom selected from B, N, O or S.
- the present invention also provides a pharmaceutical composition for the prevention or treatment of obesity, diabetes or fatty liver, comprising a compound of formula I or a pharmaceutically acceptable salt thereof.
- the present invention also provides a method of treating obesity, diabetes or fatty liver by administering an effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof to an obese, diabetic or fatty liver patient.
- novel compound of formula I of the present invention or a pharmaceutically acceptable salt thereof exhibits excellent activity against GDH, and thus can be usefully used as a medicament for the prevention or treatment of obesity, diabetes or fatty liver.
- the present invention relates to the following novel compounds of formula I or pharmaceutically acceptable salts thereof.
- R 1 is alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl or heteroaryl,
- R 2 is NR 3 R 4 ,
- R 3 and R 4 are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, heteroaryl, alkylcarbonyl, carboxyl or alkoxycarbonyl,
- the cycloalkyl, heterocyclic, aryl or heteroaryl is one selected from the group consisting of alkyl, alkenyl, alkynyl, hydroxy, halogen, amino, nitro, cyano, carbonyl, carboxyl, alkoxy, aryl and aryloxy. Can be substituted with the above substituents,
- alkyl, alkenyl or alkynyl may be substituted with one or more substituents selected from the group consisting of hydroxy, halogen, amino, nitro, cyano, carbonyl, carboxyl, alkoxy, cycloalkyl, heterocyclic, aryl and heteroaryl.
- substituents selected from the group consisting of hydroxy, halogen, amino, nitro, cyano, carbonyl, carboxyl, alkoxy, cycloalkyl, heterocyclic, aryl and heteroaryl.
- alkyl is C 1-30 alkyl
- Alkoxy is C 1-30 alkoxy
- Alkenyl is C 2-30 alkenyl
- Alkynyl is C 2-30 alkynyl
- Cycloalkyl is C 3-30 cycloalkyl
- Aryl is C 5-30 aryl
- Heterocyclic is a heterocyclic having 3 to 30 ring atoms in which one or more ring carbons are each replaced by a heteroatom selected from B, N, O or S,
- Heteroaryl is a heteroaryl having 3 to 30 ring atoms in which one or more ring carbons are each replaced with a heteroatom selected from B, N, O or S.
- the present invention relates to a compound of formula (I): or a pharmaceutically acceptable salt thereof.
- R 1 is aryl or heteroaryl
- R 2 is NR 3 R 4 ,
- R 3 and R 4 are independently hydrogen, alkyl, alkenyl, alkynyl, alkylcarbonyl, carboxyl or alkoxycarbonyl,
- the aryl or heteroaryl may be substituted with one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, hydroxy, halogen, amino, nitro, cyano, carbonyl, carboxyl, alkoxy, aryl and aryloxy, ,
- alkyl, alkenyl or alkynyl may be substituted with one or more substituents selected from the group consisting of hydroxy, halogen, amino, nitro, cyano, carbonyl, carboxyl and alkoxy,
- alkyl is C 1-30 alkyl
- Alkoxy is C 1-30 alkoxy
- Alkenyl is C 2-30 alkenyl
- Alkynyl is C 2-30 alkynyl
- Aryl is C 5-30 aryl
- Heteroaryl is a heteroaryl having 3 to 30 ring atoms in which one or more ring carbons are each replaced with a heteroatom selected from B, N, O or S.
- R 1 is aryl
- R 2 is NR 3 R 4 ,
- R 3 and R 4 are independently hydrogen or alkoxycarbonyl
- the aryl may be substituted with one or more substituents selected from the group consisting of alkyl, halogen, nitro, alkoxy, aryl and aryloxy,
- the alkyl may be substituted with one or more halogen
- Alkoxy is C 1 - 30 alkoxy
- Aryl is C 5 - relates to an acceptable salt of compound 30 aryl or a pharmaceutical.
- the present invention may include the following compound or a pharmaceutically acceptable salt thereof.
- the present invention relates to the following compounds or pharmaceutically acceptable salts thereof.
- alkyl means a linear or branched hydrocarbon group, substituted or unsubstituted, with one or more functional groups. Unless otherwise specified, “alkyl” groups preferably contain 1 to 30 carbon atoms. Preferably, the “alkyl” group may be methyl, ethyl, propyl, isopropyl, butyl, but is not limited thereto.
- Alkoxy refers to a functional group in which the alkyl group as defined above is bonded through an oxygen bridge, -0-alkyl, which is substituted or unsubstituted with one or more functional groups. It preferably contains 1 to 30 carbon atoms.
- Alkenyl means a linear, branched or cyclic hydrocarbon group having one or more unsaturated carbon-carbon bonds, substituted or unsubstituted, with one or more functional groups. Unless otherwise specified, it preferably contains 2 to 30 carbon atoms.
- Alkynyl means a linear or branched hydrocarbon group having one or more carbon-carbon triple bonds, substituted or unsubstituted with one or more functional groups. Unless otherwise specified, it preferably contains 2 to 30 carbon atoms.
- Cycloalkyl means a cyclic or polycyclic hydrocarbon group, substituted or unsubstituted, with one or more functional groups. Unless otherwise specified, it preferably contains 3 to 30 carbon atoms.
- the "cycloalkyl” group can be, but is not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, adamantane.
- Aryl means an aromatic group having 6 to 30 ring carbons, substituted or unsubstituted, with one or more functional groups.
- the "aryl” group may be phenyl or naphthyl, but is not limited thereto.
- Aryloxy includes the aryl group, which is optionally substituted, attached to an oxygen atom, and preferably may be phenoxy, but is not limited thereto.
- Heterocyclic means a non-aromatic group in which one or more ring carbons, substituted or unsubstituted with one or more functional groups, are each replaced by a heteroatom selected from B, N, O or S. Unless otherwise specified, it preferably contains 3 to 30 ring atoms.
- Heteroaryl refers to an aromatic group in which one or more ring carbons, substituted or unsubstituted with one or more functional groups, are each replaced with a heteroatom selected from B, N, O or S. Unless otherwise specified, it preferably contains 3 to 30 ring atoms.
- the present invention also relates to a pharmaceutical composition for the prevention or treatment of obesity, diabetes or fatty liver, comprising the compound of formula I or a pharmaceutically acceptable salt thereof.
- the present invention also relates to a method of treating obesity, diabetes or fatty liver, comprising administering an effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof to an obese, diabetic or fatty liver patient.
- the pharmaceutically acceptable salt is an organic acid selected from the group consisting of oxalic acid, maleic acid, fumaric acid, malic acid, tartaric acid, citric acid and benzoic acid, or an acid addition salt formed by an inorganic acid selected from the group consisting of hydrochloric acid, sulfuric acid, phosphoric acid and hydrobromic acid. It may be in the form of, but is not limited thereto.
- compositions of the present invention may be prepared as oral or parenteral preparations.
- Pharmaceutical formulations for oral or parenteral administration may be unit dosage forms such as, for example, tablets, dispersible tablets, coated tablets, effervescent tablets, capsules, suspension powders, suspensions, suppositories, or ampoules. These are produced by known methods, for example by processes such as mixing, granulating, coating or freeze drying.
- compositions for oral administration are prepared by combining the active ingredient with a solid carrier, granulating the mixture obtained if necessary, and processing the mixture or granules after addition of a suitable additive, if necessary, to obtain a tablet or coated tablet core.
- a suitable additive if necessary, to obtain a tablet or coated tablet core.
- the suitable carrier may include sugar (eg, lactose, sucrose, mannitol or sorbitol), cellulose, calcium phosphate (eg, tricalcium phosphate or calcium hydrogen phosphate) as a filler; Binders may include starch (eg, corn, wheat, rice or potato starch), gelatin, tragacanth, methylcellulose, polyvinylpyrrolidone, and the like; Disintegrants may include starch, polyvinylpyrrolidone, agar, alginic acid, or sodium alginate.
- sugar eg, lactose, sucrose, mannitol or sorbitol
- cellulose eg, calcium phosphate (eg, tricalcium phosphate or calcium hydrogen phosphate)
- Binders may include starch (eg, corn, wheat, rice or potato starch), gelatin, tragacanth, methylcellulose, polyvinylpyrrolidone, and the like
- Disintegrants may include star
- the additive may include salicylic acid, talc, stearic acid, magnesium stearate, calcium stearate, polyethylene glycol, and the like as a lubricant.
- aqueous solution of the active ingredient in a water-soluble form for example a water-soluble salt form.
- the dosage of the active ingredient is determined according to various factors such as the activity and duration of action of the active ingredient, the severity or symptoms of the disease to be treated, the method of administration, the species, sex, age, weight of the warm-blooded animal and the individual condition of the warm-blooded animal. Can be.
- R 1 is If it is a case, it is written as a representative
- Step a (E)-3-(dimethylamino)-1-(4-nitrophenyl)prop-2-en-1-one[(E)-3-(dimethylamino)-1-(4-nitrophenyl) Preparation of prop-2-en-1-one]
- Step b Preparation of 4-(4-nitrophenyl)pyrimidin-2-amine [4-(4-Nitrophenyl)pyrimidin-2-amine]
- Step c N,N-di-t-butyloxycarbonyl-4-(4-nitrophenyl)pyrimidin-2-amine [N,N-di-t-butyloxycarbonyl-4-(4-Nitrophenyl)pyrimidin- 2-amine]
- Step d N,N-di-t-butyloxycarbonyl-4-(4-aminophenyl)pyrimidin-2-amine [N,N-di-t-butyloxycarbonyl-4-(4-aminophenyl)pyrimidin- 2-amine]
- Step e N-(4-(2-(N,N-di-t-butyloxycarbonyl)aminopyrimidin-4-yl)phenyl)-4-bromobenzamide[N-(4-(2 Preparation of -(N,N-di-t-butyloxycarbonyl)aminopyrimidin-4-yl)phenyl)-4-bromobenzamide]
- Step f N-(4-(2-aminopyrimidin-4-yl)phenyl)-4-bromobenzamide [N-(4-(2-aminopyrimidin-4-yl)phenyl)-4-bromobenzamide]
- step e To the compound F of step e (42 mg, 0.1 mmol) was added 4 normal hydrogen chloride (0.7 mL) dissolved in dioxane, and the mixture was stirred at room temperature for 12 hours. The solvent was concentrated by evaporation in vacuo and recrystallized.
- R 2 is If it is a case, it is written as a representative
- Step e N-(4-(2-(N,N-di-t-butyloxycarbonyl)aminopyrimidin-4-yl)phenyl)-2-fluorobenzamide [N-(4-(2 Preparation of -(N,N-di-t-butyloxycarbonyl)aminopyrimidin-4-yl)phenyl)-2-fluorobenzamide]
- Step f N-(4-(2-aminopyrimidin-4-yl)phenyl)-2-fluorobenzamide [N-(4-(2-aminopyrimidin-4-yl)phenyl)-2-fluorobenzamide]
- R 3 is If it is a case, it is written as a representative
- Step e N-(4-(2-(N,N-di-t-butyloxycarbonyl)aminopyrimidin-4-yl)phenyl)benzamide[N-(4-(2-(N,N -di-t-butyloxycarbonyl)aminopyrimidin-4-yl)phenyl)benzamide]
- Step f Preparation of N-(4-(2-aminopyrimidin-4-yl)phenyl)benzamide [N-(4-(2-aminopyrimidin-4-yl)phenyl)benzamide]
- step e To the compound F of step e (30 mg, 0.1 mmol) was added 4 normal hydrogen chloride (0.6 mL) dissolved in dioxane, and the mixture was stirred at room temperature for 12 hours. The solvent was concentrated by evaporation in vacuo and recrystallized.
- the following compound 1 was prepared in the following manner.
- Compound 11 was prepared in the following manner.
- the following compound 16 was prepared by the following method.
- the following compound 22 was prepared by the following method.
- the following compound 28 was prepared by the following method.
- a sufficient amount of cells was obtained by culturing the INS-1 cell line under normal cell culture conditions (37°C, 5% CO 2 ). Immediately before use in the experiment, a culture dish of INS-1 cells was placed on ice, and the culture medium was removed, followed by washing with cold phosphate-buffered saline (PBS) (WELGENE, LB 001-02) to obtain a cell pellet.
- PBS cold phosphate-buffered saline
- GDH Glutamate Dehydrogenase
- the concentration of Cell lysate was prepared by dilution to 30 ⁇ g/50 ⁇ l or 100 ⁇ g/50 ⁇ l using Assay buffer with reference to the measured protein concentration.
- the prepared cell lysate + vehicle or compound + reaction mix was added according to the volume defined in the protocol of the Glutamate Dehydrogenase (GDH) Activity Colorimetric Assay Kit, reacted at 37° C., and absorbance at 450 nm was measured using a kinetic method.
- GDH Glutamate Dehydrogenase
- the compounds of the present invention exhibit excellent GDH activity.
Abstract
Description
화합물번호 | 구조식 | 화합물명 |
1 | N-(4-(2-(N,N-디-t-부틸옥시카보닐)아미노피리미딘-4-일)페닐)-4-브로모벤즈아마이드[N-(4-(2-(N,N-di-t-butyloxycarbonyl)aminopyrimidin-4-yl)phenyl)-4-bromobenzamide] | |
2 | N-(4-(2-(N,N-디-t-부틸옥시카보닐)아미노피리미딘-4-일)페닐)-4-클로로-3-메톡시벤즈아마이드[N-(4-(2-(N,N-di-t-butyloxycarbonyl)aminopyrimidin-4-yl)phenyl)-4-chloro-3-methoxybenzamide] | |
3 | N-(4-(2-(N,N-디-t-부틸옥시카보닐)아미노피리미딘-4-일)페닐)-4-클로로벤즈아마이드[N-(4-(2-(N,N-di-t-butyloxycarbonyl)aminopyrimidin-4-yl)phenyl)-4-chlorobenzamide] | |
4 | N-(4-(2-(N,N-디-t-부틸옥시카보닐)아미노피리미딘-4-일)페닐)-3,5-디클로로벤즈아마이드[N-(4-(2-(N,N-di-t-butyloxycarbonyl)aminopyrimidin-4-yl)phenyl)-3,5-dichlorobenzamide] | |
5 | N-(4-(2-(N,N-디-t-부틸옥시카보닐)아미노피리미딘-4-일)페닐)-2-플루오로-3-(트리플루오로메틸)벤즈아마이드[N-(4-(2-(N,N-di-t-butyloxycarbonyl)aminopyrimidin-4-yl)phenyl)-2-fluoro-3-(trifluoromethyl)benzamide] | |
6 | N-(4-(2-아미노피리미딘-4-일)페닐)-4-브로모벤즈아마이드[N-(4-(2-aminopyrimidin-4-yl)phenyl)-4-bromobenzamide] | |
7 | N-(4-(2-아미노피리미딘-4-일)페닐)-4-클로로-3-메톡시벤즈아마이드[N-(4-(2-aminopyrimidin-4-yl)phenyl)-4-chloro-3-methoxybenzamide] | |
8 | N-(4-(2-아미노피리미딘-4-일)페닐)-4-클로로벤즈아마이드[N-(4-(2-aminopyrimidin-4-yl)phenyl)-4-chlorobenzamide] | |
9 | N-(4-(2-아미노피리미딘-4-일)페닐)-3,5-디클로로벤즈아마이드[N-(4-(2-aminopyrimidin-4-yl)phenyl)-3,5-dichlorobenzamide] | |
10 | N-(4-(2-아미노피리미딘-4-일)페닐)-2-플루오로-3-(트리플루오로메틸)벤즈아마이드[N-(4-(2-aminopyrimidin-4-yl)phenyl)-2-fluoro-3-(trifluoromethyl)benzamide] | |
11 | N-(4-(2-(N,N-디-t-부틸옥시카보닐)아미노피리미딘-4-일)페닐)-2-플루오로벤즈아마이드[N-(4-(2-(N,N-di-t-butyloxycarbonyl)aminopyrimidin-4-yl)phenyl)-2-fluorobenzamide] | |
12 | N-(4-(2-(N,N-디-t-부틸옥시카보닐)아미노피리미딘-4-일)페닐)-3-플루오로벤즈아마이드[N-(4-(2-(N,N-di-t-butyloxycarbonyl)aminopyrimidin-4-yl)phenyl)-3-fluorobenzamide] | |
13 | N-(4-(2-(N,N-디-t-부틸옥시카보닐)아미노피리미딘-4-일)페닐)-4-플루오로벤즈아마이드[N-(4-(2-(N,N-di-t-butyloxycarbonyl)aminopyrimidin-4-yl)phenyl)-4-fluorobenzamide] | |
14 | N-(4-(2-(N,N-디-t-부틸옥시카보닐)아미노피리미딘-4-일)페닐)-3-클로로벤즈아마이드[N-(4-(2-(N,N-di-t-butyloxycarbonyl)aminopyrimidin-4-yl)phenyl)-3-chlorobenzamide] | |
15 | N-(4-(2-(N,N-디-t-부틸옥시카보닐)아미노피리미딘-4-일)페닐)-4-(트리플루오로메틸)벤즈아마이드[N-(4-(2-(N,N-di-t-butyloxycarbonyl)aminopyrimidin-4-yl)phenyl)-4-(trifluoromethyl)benzamide] | |
16 | N-(4-(2-아미노피리미딘-4-일)페닐)-2-플루오로벤즈아마이드[N-(4-(2-aminopyrimidin-4-yl)phenyl)-2-fluorobenzamide] | |
17 | N-(4-(2-아미노피리미딘-4-일)페닐)-3-플루오로벤즈아마이드[N-(4-(2-aminopyrimidin-4-yl)phenyl)-3-fluorobenzamide] | |
18 | N-(4-(2-아미노피리미딘-4-일)페닐)-4-플루오로벤즈아마이드[N-(4-(2-aminopyrimidin-4-yl)phenyl)-4-fluorobenzamide] | |
19 | N-(4-(2-아미노피리미딘-4-일)페닐)-3-클로로벤즈아마이드[N-(4-(2-aminopyrimidin-4-yl)phenyl)-3-chlorobenzamide] | |
20 | N-(4-(2-아미노피리미딘-4-일)페닐)-4-(트리플루오로메틸)벤즈아마이드[N-(4-(2-aminopyrimidin-4-yl)phenyl)-4-(trifluoromethyl)benzamide] | |
21 | N-(4-(2-아미노피리미딘-4-일)페닐)-4-페녹시벤즈아마이드[N-(4-(2-aminopyrimidin-4-yl)phenyl)-4-phenoxybenzamide] | |
22 | N-(4-(2-(N,N-디-t-부틸옥시카보닐)아미노피리미딘-4-일)페닐)벤즈아마이드[N-(4-(2-(N,N-di-t-butyloxycarbonyl)aminopyrimidin-4-yl)phenyl)benzamide] | |
23 | N-(4-(2-(N,N-디-t-부틸옥시카보닐)아미노피리미딘-4-일)페닐)-2-메톡시벤즈아마이드[N-(4-(2-(N,N-di-t-butyloxycarbonyl)aminopyrimidin-4-yl)phenyl)-2-methoxybenzamide] | |
24 | N-(4-(2-(N,N-디-t-부틸옥시카보닐)아미노피리미딘-4-일)페닐)-4-플루오로벤즈아마이드[N-(4-(2-(N,N-di-t-butyloxycarbonyl)aminopyrimidin-4-yl)phenyl)-4-nitrobenzamide] | |
25 | N-(4-(2-(N,N-디-t-부틸옥시카보닐)아미노피리미딘-4-일)페닐)-4-아이오도벤즈아마이드[N-(4-(2-(N,N-di-t-butyloxycarbonyl)aminopyrimidin-4-yl)phenyl)-4-iodobenzamide] | |
26 | N-(4-(2-(N,N-디-t-부틸옥시카보닐)아미노피리미딘-4-일)페닐)-3,5-디메틸벤즈아마이드[N-(4-(2-(N,N-di-t-butyloxycarbonyl)aminopyrimidin-4-yl)phenyl)-3,5-dimethylbenzamide] | |
27 | N-(4-(2-(N,N-디-t-부틸옥시카보닐)아미노피리미딘-4-일)페닐)-4-에틸벤즈아마이드[N-(4-(2-(N,N-di-t-butyloxycarbonyl)aminopyrimidin-4-yl)phenyl)-4-ethylbenzamide] | |
28 | N-(4-(2-아미노피리미딘-4-일)페닐)벤즈아마이드[N-(4-(2-aminopyrimidin-4-yl)phenyl)benzamide] | |
29 | N-(4-(2-아미노피리미딘-4-일)페닐)-2-메톡시벤즈아마이드[N-(4-(2-aminopyrimidin-4-yl)phenyl)-2-methoxybenzamide] | |
30 | N-(4-(2-아미노피리미딘-4-일)페닐)-4-니트로벤즈아마이드[N-(4-(2-aminopyrimidin-4-yl)phenyl)-4-nitrobenzamide] | |
31 | N-(4-(2-아미노피리미딘-4-일)페닐)-4-아이오도벤즈아마이드[N-(4-(2-aminopyrimidin-4-yl)phenyl)-4-iodobenzamide] | |
32 | N-(4-(2-아미노피리미딘-4-일)페닐)-3,5-디메틸벤즈아마이드[N-(4-(2-aminopyrimidin-4-yl)phenyl)-3,5-dimethylbenzamide] | |
33 | N-(4-(2-아미노피리미딘-4-일)페닐)-4-에틸벤즈아마이드[N-(4-(2-aminopyrimidin-4-yl)phenyl)-4-ethylbenzamide] |
농도 (μM) | Enzyme activity (fold) | |
DMSO | - | 1 |
화합물 6 | 0.2 | 2.14 |
2 | 6.93 | |
화합물 7 | 0.2 | 1.94 |
2 | 3.23 | |
화합물 8 | 0.2 | 1.34 |
2 | 11.05 | |
화합물 9 | 0.2 | 1.13 |
2 | 6.43 | |
화합물 10 | 0.2 | 2.08 |
2 | 10.83 |
Claims (7)
- 하기 화학식 Ⅰ의 화합물 또는 이의 약제학적으로 허용가능한 염:[화학식 Ⅰ]상기 식에서,R1은 알킬, 알케닐, 알키닐, 시클로알킬, 헤테로시클릭, 아릴 또는 헤테로아릴이고,R2는 NR3R4이고,상기 R3 및 R4는 독립적으로 수소, 알킬, 알케닐, 알키닐, 시클로알킬, 헤테로시클릭, 아릴, 헤테로아릴, 알킬카보닐, 카복실 또는 알콕시카보닐이고,상기 시클로알킬, 헤테로시클릭, 아릴 또는 헤테로아릴은 알킬, 알케닐, 알키닐, 히드록시, 할로겐, 아미노, 니트로, 시아노, 카보닐, 카복실, 알콕시, 아릴 및 아릴옥시로 이루어진 군으로부터 선택된 하나 이상의 치환기로 치환될 수 있고,상기 알킬, 알케닐 또는 알키닐은 히드록시, 할로겐, 아미노, 니트로, 시아노, 카보닐, 카복실 및 알콕시로 이루어진 군으로부터 선택된 하나 이상의 치환기로 치환될 수 있으며,여기서, 알킬은 C1-30 알킬이고,알콕시는 C1-30 알콕시이고,알케닐은 C2-30 알케닐이고,알키닐은 C2-30 알키닐이고,시클로알킬은 C3-30 시클로알킬이고,아릴은 C5-30 아릴이고,헤테로시클릭은 하나 이상의 고리 탄소가 각각 B, N, O 또는 S로부터 선택된 헤테로원자로 대체되는 3 내지 30개의 고리 원자를 갖는 헤테로시클릭이고,헤테로아릴은 하나 이상의 고리 탄소가 각각 B, N, O 또는 S로부터 선택된 헤테로원자로 대체되는 3 내지 30개의 고리 원자를 갖는 헤테로아릴임.
- 하기 화학식 Ⅰ의 화합물 또는 이의 약제학적으로 허용가능한 염:[화학식 Ⅰ]상기 식에서,R1은 아릴 또는 헤테로아릴이고,R2는 NR3R4이고,상기 R3 및 R4는 독립적으로 수소, 알킬, 알케닐, 알키닐, 알킬카보닐, 카복실 또는 알콕시카보닐이고,상기 아릴 또는 헤테로아릴은 알킬, 알케닐, 알키닐, 히드록시, 할로겐, 아미노, 니트로, 시아노, 카보닐, 카복실, 알콕시, 아릴 및 아릴옥시로 이루어진 군으로부터 선택된 하나 이상의 치환기로 치환될 수 있고,상기 알킬, 알케닐 또는 알키닐은 히드록시, 할로겐, 아미노, 니트로, 시아노, 카보닐, 카복실 및 알콕시로 이루어진 군으로부터 선택된 하나 이상의 치환기로 치환될 수 있으며,여기서, 알킬은 C1-30 알킬이고,알콕시는 C1-30 알콕시이고,알케닐은 C2-30 알케닐이고,알키닐은 C2-30 알키닐이고,아릴은 C5-30 아릴이고,헤테로아릴은 하나 이상의 고리 탄소가 각각 B, N, O 또는 S로부터 선택된 헤테로원자로 대체되는 3 내지 30개의 고리 원자를 갖는 헤테로아릴임.
- 제1항의 화합물 또는 이의 약제학적으로 허용가능한 염을 포함하는 비만, 당뇨병 또는 지방간의 예방 또는 치료용 약학적 조성물.
- 비만, 당뇨병 또는 지방간 환자에게 제1항의 화합물 또는 이의 약제학적으로 허용가능한 염의 유효량을 투여하는 것을 포함하는 비만, 당뇨병 또는 지방간을 예방 또는 치료하는 방법.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/297,198 US20220000868A1 (en) | 2018-11-26 | 2018-11-26 | Novel 4-carbonylamino-4-phenylpyrimidine compound or pharmaceutically acceptable salt thereof |
PCT/KR2018/014574 WO2020111283A1 (ko) | 2018-11-26 | 2018-11-26 | 신규한 4-카보닐아미노-4-페닐피리미딘 화합물 또는 이의 약제학적으로 허용가능한 염 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/KR2018/014574 WO2020111283A1 (ko) | 2018-11-26 | 2018-11-26 | 신규한 4-카보닐아미노-4-페닐피리미딘 화합물 또는 이의 약제학적으로 허용가능한 염 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020111283A1 true WO2020111283A1 (ko) | 2020-06-04 |
Family
ID=70852804
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2018/014574 WO2020111283A1 (ko) | 2018-11-26 | 2018-11-26 | 신규한 4-카보닐아미노-4-페닐피리미딘 화합물 또는 이의 약제학적으로 허용가능한 염 |
Country Status (2)
Country | Link |
---|---|
US (1) | US20220000868A1 (ko) |
WO (1) | WO2020111283A1 (ko) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002046170A2 (en) * | 2000-12-06 | 2002-06-13 | Signal Pharmaceuticals, Inc. | Anilinopyrimidine derivatives as jnk pathway inhibitors and compositions and methods related thereto |
WO2004041789A1 (en) * | 2002-11-01 | 2004-05-21 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of jak and other protein kinases |
KR20050042478A (ko) * | 2002-08-14 | 2005-05-09 | 버텍스 파마슈티칼스 인코포레이티드 | 프로테인 키나아제 억제제 및 이의 용도 |
KR20080040027A (ko) * | 2005-09-02 | 2008-05-07 | 아스테라스 세이야쿠 가부시키가이샤 | Rock 억제제로서 아미드 유도체 |
KR20080110998A (ko) * | 2006-01-30 | 2008-12-22 | 엑셀리시스, 인코포레이티드 | Jak2 조절자로서 4아릴2아미노피리미딘 또는 4아릴2아미노알킬피리미딘 및 이들을 포함하는 약제학적 조성물 |
-
2018
- 2018-11-26 US US17/297,198 patent/US20220000868A1/en active Pending
- 2018-11-26 WO PCT/KR2018/014574 patent/WO2020111283A1/ko active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002046170A2 (en) * | 2000-12-06 | 2002-06-13 | Signal Pharmaceuticals, Inc. | Anilinopyrimidine derivatives as jnk pathway inhibitors and compositions and methods related thereto |
KR20050042478A (ko) * | 2002-08-14 | 2005-05-09 | 버텍스 파마슈티칼스 인코포레이티드 | 프로테인 키나아제 억제제 및 이의 용도 |
WO2004041789A1 (en) * | 2002-11-01 | 2004-05-21 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of jak and other protein kinases |
KR20080040027A (ko) * | 2005-09-02 | 2008-05-07 | 아스테라스 세이야쿠 가부시키가이샤 | Rock 억제제로서 아미드 유도체 |
KR20080110998A (ko) * | 2006-01-30 | 2008-12-22 | 엑셀리시스, 인코포레이티드 | Jak2 조절자로서 4아릴2아미노피리미딘 또는 4아릴2아미노알킬피리미딘 및 이들을 포함하는 약제학적 조성물 |
Also Published As
Publication number | Publication date |
---|---|
US20220000868A1 (en) | 2022-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2011043568A2 (en) | Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same | |
WO2021118318A2 (ko) | 신규한 인돌 유도체 및 이의 용도 | |
WO2019168237A1 (ko) | 신규 화합물 및 이를 유효성분으로 함유하는 섬유증 또는 비알코올성 지방간염의 예방, 개선 또는 치료용 조성물 | |
AU2019381113B2 (en) | Novel compound as protein kinase inhibitor, and pharmaceutical composition comprising thereof | |
WO2014109530A1 (ko) | 2-(페닐에티닐)티에노[3,4-b]피라진 유도체 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물 | |
WO2018004258A1 (ko) | 신규한 헤테로시클릭 유도체 화합물 및 이의 용도 | |
EP3827004A1 (en) | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same | |
WO2019074241A1 (ko) | 페닐아세틸렌 유도체를 포함하는 pd-1과 pd-l1의 상호작용 억제제 | |
AU2017256488B2 (en) | Quinazoline derivative or its salt and pharmaceutical composition comprising the same | |
WO2013105753A1 (en) | Substituted piperidine derivatives and methods for preparing the same | |
WO2011122815A2 (en) | Novel quinoxaline derivatives | |
WO2011049274A1 (en) | Imidazole derivatives and compositions for treating melanoma | |
WO2018056621A1 (ko) | 신규한 이미다졸일 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 | |
WO2017131425A1 (ko) | Jnk 저해 활성을 갖는 신규한 이미다졸 유도체 및 이의 용도 | |
WO2020111283A1 (ko) | 신규한 4-카보닐아미노-4-페닐피리미딘 화합물 또는 이의 약제학적으로 허용가능한 염 | |
WO2020013531A1 (ko) | N-(3-(이미다조[1,2-b]피리다진-3-일에티닐)-4-메틸페닐)-5-페닐-4,5-다이하이드로-1H-피라졸-1-카복사마이드 유도체 및 이를 유효성분으로 포함하는 키나아제 관련 질환 치료용 약학적 조성물 | |
WO2010032986A2 (ko) | 신규 5-(4-아미노페닐)-이소퀴놀린 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 raf 키나제의 과활성에 의해 유발되는 질환의 예방 또는 치료용 조성물 | |
EP3867249A1 (en) | Novel (isopropyl-triazolyl)pyridinyl-substituted benzooxazinone or benzothiazinone derivatives and use thereof | |
WO2014185561A1 (ko) | 신규한 화합물 또는 이의 약학적으로 허용 가능한 염 및 이를 유효성분으로 함유하는 uch-l1 관련 질환의 예방 또는 치료용 약학적 조성물 | |
WO2022203332A1 (en) | Novel indoleamine 2,3-dioxygenase inhibitors, processes for the preparation thereof and pharmaceutical compositions comprising the same | |
WO2024029877A1 (ko) | A3 아데노신 수용체 작용제로서의 신규한 퓨린 유도체 화합물 | |
WO2022250350A1 (ko) | 피페리딘디온 유도체 | |
WO2022164135A1 (ko) | 벤조티아졸 및 벤즈이미다졸 유도체, 약제학적으로 허용 가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물 | |
WO2021080346A1 (ko) | 단백질 키나아제 저해 활성을 갖는 신규한 피리디닐트리아진 유도체 및 이를 포함하는 암의 예방, 개선 또는 치료용 약학 조성물 | |
WO2023090908A1 (ko) | 신규 플라보노이드 유도체 및 이를 유효성분으로 포함하는 대사성 질환의 예방 또는 치료용 약학 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18941502 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 18941502 Country of ref document: EP Kind code of ref document: A1 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 18941502 Country of ref document: EP Kind code of ref document: A1 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC, EPO FORM 1205A DATED 28.04.2022 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC, EPO FORM 1205A DATED 28.04.2022 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC, EPO FORM 1205A DATED 28.04.2022 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 18941502 Country of ref document: EP Kind code of ref document: A1 |